BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

MSN Laboratories launches SEMABEST, the first integrated Made-in-India Semaglutide

15 April 2026 | News

SEMABEST is priced at nearly 50% lower than the innovator drug



MSN Laboratories has announced the launch of SEMABEST, its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO).

This milestone reinforces the company's commitment to expanding access to advanced therapies for chronic metabolic diseases, including type 2 diabetes. SEMABEST is priced at nearly 50% lower than the innovator drug, significantly improving affordability and patient access. The therapy is available as a pre-filled pen for subcutaneous administration.

Since 20th March 2026, the market has seen a surge of new entrants. In this evolving landscape, SEMABEST stands apart with its strong backward integration across in-house USDMF-grade API and formulation. The Pen device is also made in India complying with global regulatory standards. SEMABEST represents a significant step forward in making complex peptide therapies more accessible, affordable, and scalable for Indian patients.

"The product has demonstrated bioequivalence to the reference (innovator) drug, with its performance further validated through Phase III clinical studies conducted in direct comparison. The results showed comparable reduction in HbA1c levels, along with similar outcomes across key parameters including fasting plasma glucose (FPG), postprandial glucose (PPG) & weight loss. SEMABEST also exhibited a comparable safety profile, reinforcing its reliability as an effective therapeutic option." said Dr Kamini Desai, Head – Medical Affairs, MSN Laboratories.